Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ATNM |
---|---|---|
09:32 ET | 4184 | 1.79 |
09:34 ET | 100 | 1.81 |
09:38 ET | 6834 | 1.8 |
09:39 ET | 200 | 1.805 |
09:41 ET | 100 | 1.805 |
09:43 ET | 110 | 1.81 |
09:45 ET | 904 | 1.8 |
09:48 ET | 700 | 1.815 |
09:52 ET | 800 | 1.81 |
09:56 ET | 345 | 1.8014 |
09:59 ET | 100 | 1.805 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Actinium Pharmaceuticals Inc | 55.8M | -1.2x | --- |
Reneo Pharmaceuticals Inc | 54.2M | -1.0x | --- |
Elicio Therapeutics Inc | 52.5M | -1.0x | --- |
OS Therapies Inc | 59.3M | -9.9x | --- |
Mural Oncology PLC | 51.6M | -0.3x | --- |
enVVeno Medical Corp | 60.0M | -2.4x | --- |
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $55.8M |
---|---|
Revenue (TTM) | $81.0K |
Shares Outstanding | 31.2M |
Actinium Pharmaceuticals Inc does not pay a dividend. | |
Beta | 0.14 |
EPS | $-1.52 |
Book Value | $1.32 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | 688.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -57,665.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.